CBIO — CRESCENT BIOPHARMA, INC.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1253689 ·
Last close
$20.35
Market Cap
$561.09M
52W High
$27.41
52W Low
$9.90
ADV30
304,171
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 1,039,000 | — | -24,729,000 | -23,283,000 | 199,130,000 | 189,163,000 | 15,283,000 |
| Dec 2025 | 10,844,000 | — | -91,492,000 | -92,397,000 | 240,293,000 | 213,192,000 | 37,281,000 |
| Sep 2025 | 0 | — | -25,885,000 | -24,607,000 | 138,269,000 | 133,265,000 | 21,628,000 |
| Jun 2025 | 0 | — | -21,030,000 | -21,790,000 | 157,433,000 | 152,645,000 | 18,179,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-69,618,000
Investing CF
$-81,066,000
Financing CF
$317,525,000
CapEx
$-80,926,000
Dividends Paid
—
Buybacks
$0
EPS Diluted TTM
$-10.91
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-195,092,000
Inventory
—
Receivables
$0
ST Investments
—
EBIT TTM
$-159,004,000
Pretax Income TTM
$-160,077,000
Interest Exp TTM
$1,073,000
Analysts
7
Yahoo Snapshot (yfinance, live)
Total Revenue
$11,883,000
EBITDA
—
Free Cash Flow
—
Enterprise Value
$505,550,624
Total Cash
$189,163,008
Total Debt
$1,543,000
Shares Out
27,571,935
Trailing EPS
$-5.90
Book Value
$5.41
ROE
—
ROA
—
Div Yield
—
Annual Trend (SEC EDGAR, last 2y)
Revenues vs Net Income (last 2y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 10,844,000 | -152,632,000 | -153,942,000 | 240,293,000 | 37,281,000 | — | -71,532,000 |
| Dec 2024 | — | — | — | 35,617,000 | 51,096,000 | — | — |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-2.94
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| ALT | Altimmune, Inc. | $569.81M | $2.93 | — |
| ARVN | ARVINAS, INC. | $575.53M | $8.92 | — |
| GYRE | GYRE THERAPEUTICS, INC. | $576.35M | $5.94 | — |
| RIGL | RIGEL PHARMACEUTICALS INC | $539.71M | $29.17 | — |
| NIKA | NIKA PHARMACEUTICALS, INC | $534.76M | $0.51 | — |
News headlines (Yahoo Finance, 1h cache)
Crescent Biopharma Announces Grants of Inducement Awards
2026-05-12 20:30 · Yahoo
Crescent Biopharma to Present at May Investor Conferences
2026-05-06 11:30 · Yahoo
Crescent Biopharma Reports First Quarter 2026 Financial Results and Recent Business Highlights
2026-04-29 20:15 · Yahoo
Crescent Biopharma: Q4 Earnings Snapshot
2026-02-26 13:05 · Yahoo
Crescent Biopharma Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights
2026-02-26 12:30 · Yahoo
Crescent Biopharma to Present at March Investor Conferences
2026-02-23 12:30 · Yahoo
Crescent Biopharma Announces First Patient Dosed in ASCEND Phase 1/2 Clinical Trial of CR-001 for the Treatment of Advanced Solid Tumors
2026-02-18 12:30 · Yahoo
Crescent Biopharma to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026
2026-02-05 12:30 · Yahoo
Kelun-Biotech Receives Investigational New Drug Approval for ITGB6-Targeted ADC SKB105 from the NMPA
2026-01-05 12:00 · Yahoo
Crescent Biopharma Announces Regulatory Clearances of IND Applications for CR-001, a PD-1 x VEGF Bispecific Antibody and CR-003, an ITGB6-targeted ADC, for the Treatment of Solid Tumors
2026-01-05 12:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.